BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024
BrainsWay (NASDAQ & TASE: BWAY), a leader in noninvasive neurostimulation treatments for mental health disorders, has announced its plan to report second quarter 2024 financial results on August 6, 2024, before U.S. financial markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss results and provide operational updates.
Investors can access the call via phone or webcast. The webcast will be available for replay for 30 days on BrainsWay's investor relations website. This announcement provides shareholders and analysts with a scheduled opportunity to review the company's financial performance and engage with management about recent developments and future prospects.
BrainsWay (NASDAQ & TASE: BWAY), leader nei trattamenti non invasivi di neurostimolazione per disturbi mentali, ha annunciato il suo piano di riportare i risultati finanziari del secondo trimestre 2024 il 6 agosto 2024, prima dell'apertura dei mercati finanziari statunitensi. L'azienda organizzerà una chiamata e un webcast alle 8:30 AM Eastern Time per discutere i risultati e fornire aggiornamenti operativi.
Gli investitori possono accedere alla chiamata tramite telefono o webcast. Il webcast sarà disponibile per la riproduzione per 30 giorni sul sito web delle relazioni con gli investitori di BrainsWay. Questo annuncio offre agli azionisti e agli analisti un'opportunità programmata per rivedere le performance finanziarie della società e interagire con la direzione riguardo agli sviluppi recenti e alle prospettive future.
BrainsWay (NASDAQ & TASE: BWAY), líder en tratamientos de neuroestimulación no invasiva para trastornos de salud mental, ha anunciado su plan de informar sobre los resultados financieros del segundo trimestre de 2024 el 6 de agosto de 2024, antes de la apertura de los mercados financieros en EE. UU. La compañía organizará una llamada de conferencia y un webcast a las 8:30 AM hora del Este para discutir los resultados y proporcionar actualizaciones operativas.
Los inversores pueden acceder a la llamada por teléfono o webcast. El webcast estará disponible para su reproducción durante 30 días en el sitio web de relaciones con los inversores de BrainsWay. Este anuncio proporciona a los accionistas y analistas una oportunidad programada para revisar el rendimiento financiero de la empresa y interactuar con la gerencia sobre los desarrollos recientes y las perspectivas futuras.
BrainsWay (NASDAQ & TASE: BWAY)는 정신 건강 장애를 위한 비침습적 신경 자극 치료의 선두주자로서, 2024년 2분기 재무 결과를 2024년 8월 6일 미국 금융 시장 개장 전에 발표할 계획이라고 밝혔습니다. 회사는 동부 표준시 기준 오전 8:30에 결과를 논의하고 운영 업데이트를 제공하는 컨퍼런스 콜 및 웹캐스트를 개최할 것입니다.
투자자들은 전화 또는 웹캐스트를 통해 콜에 참여할 수 있습니다. 웹캐스트는 BrainsWay의 투자자 관계 웹사이트에서 30일 동안 재생이 가능합니다. 이 발표는 주주와 분석가에게 회사의 재무 성과를 검토하고 최근 개발 및 향후 전망에 대해 경영진과 소통할 수 있는 예정된 기회를 제공합니다.
BrainsWay (NASDAQ & TASE: BWAY), leader dans les traitements de neurostimulation non invasive pour les troubles de la santé mentale, a annoncé son intention de présenter les résultats financiers du deuxième trimestre 2024 le 6 août 2024, avant l'ouverture des marchés financiers américains. La société tiendra une conférence téléphonique et un webcast à 8h30, heure de l'Est, pour discuter des résultats et fournir des mises à jour opérationnelles.
Les investisseurs peuvent accéder à l'appel par téléphone ou par webcast. Le webcast sera disponible en replay pendant 30 jours sur le site web des relations avec les investisseurs de BrainsWay. Cette annonce offre aux actionnaires et aux analystes une occasion programmée de passer en revue la performance financière de l'entreprise et d'échanger avec la direction sur les récents développements et les perspectives d'avenir.
BrainsWay (NASDAQ & TASE: BWAY), ein führendes Unternehmen in der nicht-invasiven Neurostimulationsbehandlung für psychische Erkrankungen, hat seinen Plan bekannt gegeben, die finanziellen Ergebnisse des zweiten Quartals 2024 am 6. August 2024 vor der Eröffnung der US-Finanzmärkte zu berichten. Das Unternehmen wird um 8:30 AM Eastern Time eine Telefonkonferenz und einen Webcast veranstalten, um die Ergebnisse zu besprechen und operative Updates zu geben.
Investoren können über Telefon oder Webcast auf die Konferenz zugreifen. Der Webcast wird für 30 Tage auf der Website für Investor Relations von BrainsWay verfügbar sein. Diese Ankündigung bietet Aktionären und Analysten die geplante Möglichkeit, die finanzielle Leistung des Unternehmens zu überprüfen und mit dem Management über aktuelle Entwicklungen und zukünftige Aussichten zu sprechen.
- None.
- None.
BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
| Date: | Tuesday, August 6, 2024 |
| Time: | 8:30 AM Eastern Time |
| United States: | 1-877-300-8521 |
| International: | 1-412-317-6026 |
| Israel: | 1-80-921-2373 |
| Conference ID: | 10190847 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1679332&tp_key=1f7beb24a2 |
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors LLC
britchie@lifesciadvisors.com
FAQ
When will BrainsWay (BWAY) report its Q2 2024 financial results?
What time is BrainsWay's (BWAY) Q2 2024 earnings call scheduled for?
How can investors access BrainsWay's (BWAY) Q2 2024 earnings call?
How long will the replay of BrainsWay's (BWAY) Q2 2024 earnings call be available?
